{{Short description|Consumer health company}} {{Infobox company | name = Cordlife Group Limited | type = Public | traded_as = {{sgx|P8A}} | foundation = {{Start date and age|df=yes|2001|5|2}} | location_country = Singapore | area_served = China, Hong Kong, India, Indonesia, The Philippines, Malaysia (as Stemlife) and Thailand (under other brands through investment stake) | key_people = {{Unbulleted list|Wu Gang(Non-Independent Non-Executive Chairman)|Chen Xiaoling (Executive Director & Group CEO)}} | industry = Healthcare Services | products = Cord blood banking, cord lining banking, metabolic screening and other products catering to the mother & child segment | revenue = S$27.6 million (FY2024) | num_employees = 937 (FY2017) | homepage = [https://www.cordlife.com www.cordlife.com] | logo = CordLife.jpg }}{{Promotional|date=March 2026}} '''Cordlife''' '''Group Limited''', is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.<ref>{{Cite web |date=June 4, 2019 |title=Cordlife Group Limited |url=https://www.sec.gov/Archives/edgar/data/1467808/000110465919041461/a19-10484_1ex4d32.htm |access-date=2025-02-14 |website=www.sec.gov}}</ref>
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB<ref name=":7"> {{Cite web |title=Cellular Therapy Facilities |url=https://www.aabb.org/standards-accreditation/accreditation/accredited-facilities/cellular-therapy-facilities |access-date=2026-05-21 |website=www.aabb.org |language=en}} </ref>(formerly the American Association of Blood Banks) until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes.<ref name=":17">{{Cite web|url=https://straitstimes.com/singapore/cordlife-group-found-to-have-damaged-cord-blood-units-of-at-least-2150-customers|title=Cordlife Group found to have damaged cord blood units of at least 2,150 customers|date=30 November 2023|website=The Straits Times}}</ref>
== History ==
=== 2001–2007 === ''CordLife pte ltd'' was incorporated on 2 May 2001, and subsequently received a licence to operate from the Ministry of Health of Singapore in either 2001 or 2002.<ref name=":3"> {{Cite web |title=Cordlife prospectus |url=https://cordlife.listedcompany.com/misc/prospectus.pdf |archive-url=https://web.archive.org/web/20130723025131/http://cordlife.listedcompany.com/misc/prospectus.pdf |archive-date=23 July 2013 |access-date=21 May 2026}} </ref><ref name=":16">{{Cite web |title=Milestones |url=https://www.cordlife.com/sg/milestones |access-date=2026-01-22 |website=Cordlife |language=en}}</ref> In 2003, it merged with Cytomatrix LLC, and in June 2004, its holding company Cygenic Limited was listed on the Australian Securities Exchange.In 2005, the company then entered the Hong Kong and PRC markets through Cordlife Hong Kong. In 2007, Cygenic Limited was renamed to Cordlife Limited("CBB") in June, while Cordlife Hong Kong achieved ISO:9001 in August.<ref name=":3" /> CyGenics Ltd also received the 'Technology Pioneer' award from the World Economic Forum in 2007.<ref>{{Cite web |title=List of Technology Pioneers 2007 |url=https://www.weforum.org/pages/list-of-technology-pioneers-2007/ |archive-url=http://web.archive.org/web/20231204195235/https://www.weforum.org/pages/list-of-technology-pioneers-2007/ |archive-date=2023-12-04 |access-date=2026-01-22 |website=World Economic Forum |language=en}}</ref>
=== 2008–2011 === In either 2007 or 2008, their Science Park II facility was launched.<ref name=":3" /><ref name=":16" /> In September 2009, they released a cord blood unit for cerebral palsy, while on October 31, Cordlife Limited invested a 10% indirect equity stake in Guangzhou Tianhe Nuoya, a company engaged in providing cord blood banking services in Guangdong province. In 2010, The 10% indirect stake and Cordlife Hong Kong was transferred to the group. In March 2010, Cordlife also released a cord blood unit for treatment of neuroblastoma in Singapore.
On 30 June 2011, Cordlife demerged from Cordlife Limited and entered into Rights Of First Refusal (ROFR) agreement to acquire relevant businesses in Indonesia, the Philippines and India.<ref name=":3" /> === 2012–2014 === They became listed on Mainboard of SGX-ST on March 29, 2012<ref> Bizdaily, "[http://bizdaily.com.sg/newsite/sgx-sees-13-mainboard-ipos-in-2012/ SGX SEES 13 MAINBOARD IPOS IN 2012] {{Webarchive|url=https://web.archive.org/web/20140504020406/http://bizdaily.com.sg/newsite/sgx-sees-13-mainboard-ipos-in-2012/|date=2014-05-04}}", 21 December 2012 </ref> In May 2013, Cordlife moved to its fully owned, 23,000 square feet office and laboratory facility in A'Posh Bizhub, Yishun<ref> {{Cite web |title=20130513_190437_P8A_F9DE0FA6AF468EFA48257B6A003B4D4A.1.pdf |url=https://cordlife.listedcompany.com/newsroom/20130513_190437_P8A_F9DE0FA6AF468EFA48257B6A003B4D4A.1.pdf |archive-url=https://web.archive.org/web/20140503100559/http://cordlife.listedcompany.com/newsroom/20130513_190437_P8A_F9DE0FA6AF468EFA48257B6A003B4D4A.1.pdf |archive-date=3 May 2014 |access-date=21 May 2026}} </ref> In October 2013, the Group's Indian subsidiary, Cordlife Sciences (India) Pvt. Ltd.,<ref> Cordlife Sciences (India) Pvt. Ltd, "[https://www.cordlifeindia.com/ Cordlife Sciences (India) Pvt. Ltd]", 22 February 2021 </ref> introduced a metabolic screening service known as Metascreen.<ref name=":4"> India Infoline News Service, "[http://www.indiainfoline.com/Markets/News/Cordlife-launches-MetaScreen-Metabolic-Screening-Service/5822531022 Cordlife launches MetaScreen Metabolic Screening Service] {{Webarchive|url=https://web.archive.org/web/20140504015339/http://www.indiainfoline.com/Markets/News/Cordlife-launches-MetaScreen-Metabolic-Screening-Service/5822531022|date=2014-05-04}}", 22 November 2013 </ref>
=== 2015–2023 === In October 2015, they became the first company in Singapore to win Frost & Sullivan Singapore Stem Cell Company of the Year Award.<ref> {{Cite web |title=Frost & Sullivan Stem Cell Company of the Year |url=http://www.frost-apac.com/singaporeawards/popup/cordlife/ |url-status=live |archive-url=https://web.archive.org/web/20170401073821/http://www.frost-apac.com/singaporeawards/popup/cordlife/ |archive-date=2017-04-01 |access-date=15 May 2018}} </ref> Also in 2015, they were named by Forbes as one of Asia's 200 Best Under A Billion (2015)<ref> {{Cite web |title=Forbes Asia's 200 Best Under a Billion |url=https://www.forbes.com/companies/cordlife-group/ |url-status=live |archive-url=https://web.archive.org/web/20180907110305/https://www.forbes.com/companies/cordlife-group/ |archive-date=2018-09-07 |access-date=15 May 2018 |website=Forbes}} </ref>
In January 2016, Cordlife was accredited by FACT-NETCORD.<ref name=":14"> {{Cite news |date=15 January 2016 |title=CORDLIFE: Becomes one of only 6 dual-accredited private cord blood banks worldwide |url=https://www.nextinsight.net/story-archive-mainmenu-60/938-2016/10517-cordlife-is-one-of-6-dual-accredited-private-cord-blood-banks-worldwide |url-status=live |archive-url=https://web.archive.org/web/20180515112550/https://www.nextinsight.net/story-archive-mainmenu-60/938-2016/10517-cordlife-is-one-of-6-dual-accredited-private-cord-blood-banks-worldwide |archive-date=2018-05-15 |access-date=15 May 2018 |work=NextInsight}} </ref> In November 2016, Cordlife India and majority-owned Hong Kong Screening Centre received accreditation from the College of American Pathologists (CAP).<ref name=":15"> {{Cite web |date=23 November 2016 |title=Cordlife Group Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries |url=https://www.cordlife.com/news/pdf_pressReleases/2016/Cordlife_HKSC%20CAP_Accreditation_PR_20161122.pdf |url-status=live |archive-url=https://web.archive.org/web/20180515185048/https://www.cordlife.com/news/pdf_pressReleases/2016/Cordlife_HKSC%20CAP_Accreditation_PR_20161122.pdf |archive-date=2018-05-15 |access-date=15 May 2018 |website=www.cordlife.com}} </ref>
In 2019, Group CEO Michael Weiss resigned and was replaced by Tan Poh Lan.<ref> {{Cite web |date=28 February 2019 |title=Designation of new Group CEO |url=https://links.sgx.com/1.0.0/corporate-announcements/1IS3WEKB5BBLM4ZS/1b87ba61549e0c435075a1e6cb4299092f5207d14e2743cadbff46ea54debff3}} </ref>
=== 2023–Present === In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes.<ref name=":17" />On 15 December, the company was issued a six-month suspension and had to cease collecting, testing, processing and/or storing any new cord blood and human tissues. The suspension was extended by an additional three months on June 15 for Cordlife to complete the validation of its new cord blood processing method.<ref name=":18">{{Cite news|title=Cordlife allowed to resume limited cord blood banking services|url=https://www.straitstimes.com/singapore/private-cord-blood-bank-cordlife-allowed-to-resume-limited-cord-blood-banking-services?ref=inline-article|work=The Straits Times|date=2024-08-29|access-date=2026-01-29|issn=0585-3923|language=en}}</ref>
In March 2024, the group's former CEO and four other board members were arrested and released on bail.<ref>{{Cite news|title=Cordlife’s former group CEO and four directors arrested and out on bail|url=https://www.straitstimes.com/singapore/cordlife-s-former-group-ceo-and-four-board-members-arrested-and-out-on-bail?ref=more-on-this-topic|work=The Straits Times|date=2024-03-22|access-date=2026-01-29|issn=0585-3923|language=en}}</ref> In August 2024, Cordlife was permitted to resume services on a limited basis.<ref name=":18" />
Their license was subsequently renewed for one year from 14 January 2025.<ref>{{Cite news|title=Cordlife’s licences for cord blood banking, human tissue banking services renewed for a year|url=https://www.straitstimes.com/business/companies-markets/cordlifes-licences-for-cord-blood-banking-and-human-tissue-banking-services-renewed-for-a-year?ref=inline-article|work=The Straits Times|date=2025-01-15|access-date=2026-01-29|issn=0585-3923|language=en}}</ref>On 29 September, the Ministry of Health informed Cordlife that their license would be suspended after the midpoint audit found that Cordlife failed to maintain its compliance with various regulatory requirements, including governance, incident reporting and management, as well as processes for collection, testing and processing of new CBUs, the suspension coming into effect from 26 November 2025.<ref>{{Cite news|title=Cordlife will not be allowed to collect, test, process and store new cord blood from Nov 26|url=https://www.straitstimes.com/singapore/cordlife-will-not-be-allowed-to-collect-test-process-and-store-new-cord-blood-from-nov-26?ref=inline-article|work=The Straits Times|date=2025-11-26|access-date=2026-01-29|issn=0585-3923|language=en}}</ref> In October 2025, Cordlife’s executive chairman resigned less than five months into the position.<ref>{{Cite news|title=Cordlife’s executive chairman resigns after less than 5 months in the role|url=https://www.straitstimes.com/business/cordlifes-executive-chairman-resigns-after-less-than-5-months-in-the-role?ref=more-on-this-topic|work=The Straits Times|date=2025-10-31|access-date=2026-01-29|issn=0585-3923|language=en}}</ref>
On 14 January 2026, Cordlife announced that their cord blood banking service licence was renewed for a year, while its human tissue banking service licence was renewed for two years.<ref>{{Cite web |title=Cordlife's cord blood banking licence renewed for another year |url=https://www.channelnewsasia.com/singapore/cordlife-cord-blood-banking-licence-renewed-moh-5857761 |access-date=2026-01-15 |website=CNA |language=en}}</ref>
== Products and services == {{Unreferenced section|date=May 2026}}
=== Cord Blood Banking === Cordlife's cord blood banking services are available in the following countries: Singapore, Hong Kong, India, Indonesia, Malaysia, the Philippines, Thailand, Bangladesh, Myanmar and Vietnam.
=== Cord Lining Banking === Cordlife's cord lining banking services are available in the following countries: Singapore, Hong Kong, India, Indonesia, Malaysia, the Philippines, Bangladesh, Myanmar and Vietnam.
=== Non-invasive Newborn Metabolic Screening === Cordlife has already launched this newborn metabolic screening test (Metascreen) in the following countries: Hong Kong (through HealthBaby and Cordlife Hong Kong), Philippines, Indonesia and Malaysia.
=== Non-invasive Prenatal Testing === Non-invasive prenatal testing ("NIPT") is a prenatal screening test that analyses foetal DNA in the mother's blood for potential foetal chromosomal abnormalities, including Down syndrome, Edwards syndrome and Patau syndrome. Cordlife offers this service in Singapore, India, Indonesia and the Philippines.
=== Paediatric Vision Screening === Cordlife offers paediatric vision screening marketed under the brand Eyescreen, a marketing trademark of the Group's wholly owned subsidiary Cordlife Technologies Pte Ltd. Eyescreen is a safe and non-invasive paediatric vision screening service for children aged between six months and six years old. The test detects up to 11 eye conditions such as strabismus (crossed eyes) and amblyopia (lazy eye) using a device with photoscreening technology. It is abailable in Singapore
== International operations ==
=== Singapore === Cordlife Singapore<ref name=":9"> {{Cite news |title=Cordlife's CEO runs a tight ship |url=http://business.asiaone.com:80/sme-central/prime-movers/cordlifes-ceo-runs-tight-ship |archive-url=http://web.archive.org/web/20160425102948/http://business.asiaone.com:80/sme-central/prime-movers/cordlifes-ceo-runs-tight-ship |archive-date=2016-04-25 |access-date=2026-05-21 |work=AsiaOne Business |language=en}} </ref> is the country's first private cord blood bank and the corporate headquarters of the Group. Situated at A’Posh Bizhub, Yishun, Cordlife Singapore's fully owned 23,000 square feet processing and storage facility has a storage capacity of up to 650,000<ref name=":9" /> cord blood units. Since 2005, Cordlife Singapore has been accredited by AABB.<ref name=":7" /> To date, Cordlife Singapore has successfully released 14 cord blood units to its clients.<ref> {{Cite web|url=https://www.cordlife.com/sg/release-track-record|title=Cordlife Release Track Record|website=www.cordlife.com/sg|archive-url=https://web.archive.org/web/20180515183823/https://www.cordlife.com/sg/release-track-record|archive-date=2018-05-15|url-status=live|access-date=15 May 2018}} </ref> In May 2013, Cordlife Technologies Pte Ltd (“CTPL”), a wholly owned subsidiary of the Group, launched cord lining banking service in Singapore.<ref>{{Cite web |title=20130509_074752_P8A_B2125CD4AEC0DC5048257B6500818718.1 |url=https://cordlife.listedcompany.com/newsroom/20130509_074752_P8A_B2125CD4AEC0DC5048257B6500818718.1.pdf |url-status=live |archive-url=https://web.archive.org/web/20140503100430/http://cordlife.listedcompany.com/newsroom/20130509_074752_P8A_B2125CD4AEC0DC5048257B6500818718.1.pdf |archive-date=3 May 2014 |access-date=21 May 2026}}</ref> In December 2015, their facility was successfully accredited by FACT-Netcord.<ref> {{Cite web|url=http://cordlife.listedcompany.com/misc/ar2016/index.html|title=Cordlife Group Limited Annual Report 2016|website=www.cordlife.com|archive-url=https://web.archive.org/web/20180521010002/http://cordlife.listedcompany.com/misc/ar2016/index.html|archive-date=2018-05-21|url-status=live|access-date=15 May 2018}} </ref>
=== Hong Kong === Launched in 2005, Cordlife (Hong Kong) Limited (“Cordlife Hong Kong”) is a wholly owned subsidiary of the Group. Cordlife Hong Kong moved into a new facility at the Hong Kong Science Park in 2010.<ref name=":3" /> The AABB & ISO certified facility has a storage capacity for 50,000<ref name=":10">{{Cite web|url=https://parentsguidecordblood.org/en/bank/cordlife-hong-kong|title=Cordlife Hong Kong|website=parentsguidecordblood.org}}</ref> cord blood and umbilical cord units. In January 2011,<ref name=":10" /> Cordlife Hong Kong became the only private cord blood bank in Hong Kong to have released a cord blood unit for autologous (with one's own stem cells) transplantation to aid the treatment of neuroblastoma. In March 2011,<ref name=":3" /> Cordlife Hong Kong introduced CellOptima, a patented cord lining stem cell technology to extract Mesenchymal stem cells (MSCs) and Epithelial Stem Cells (EpSCs) from umbilical cord.. In 2014,<ref name=":8"> {{Cite web |last= |first= |title=Metascreen™ Hong Kong - Profile |url=http://www.metascreen.org/hk/about-metascreen/profile |archive-url=http://web.archive.org/web/20140502191023/http://www.metascreen.org/hk/about-metascreen/profile |archive-date=2014-05-02 |access-date=2026-05-21 |website=www.metascreen.org |language=en-gb}} </ref> Cordlife Hong Kong launched Metascreen, a newborn metabolic screening service, in Hong Kong. In January 2018, Cordlife acquired HealthBaby Biotech (Hong Kong) Co., Limited, the largest private cord blood bank in Hong Kong. HealthBaby is accredited by AABB, CAP, FACT and certified by [https://www.itc.gov.hk/en/quality/hkas/hoklas/about.htm HOKLAS].
=== Indonesia ===
Cordlife Indonesia has been providing cord blood processing and cryopreservation service to families in Indonesia since 2003.<ref> {{Cite web |title=Industry Watch |url=http://www.asiabiotech.com/publication/apbn/10/english/preserved-docs/1019/1094_1095.pdf |url-status=dead |archive-url=https://web.archive.org/web/20140504085558/http://www.asiabiotech.com/publication/apbn/10/english/preserved-docs/1019/1094_1095.pdf |archive-date=4 May 2014 |access-date=21 May 2026 |website=www.asiabiotech.com}} </ref> In October 2007,<ref>Emerald Emerging Markets Case Studies, “One life, one chance”: Cordlife Sciences India Pvt. Ltd. Preserving the precious gift</ref> Cordlife Indonesia opened the first and only DEPKES licensed private cord blood banking facility in Indonesia. Located in Jakarta, Cordlife Indonesia's ISO-certified processing and storage facility has a storage capacity of 30,000<ref> Departemen Kesehatan Republik Indonesia, "[http://www.cordlife.com/news/pdf_cordlifeNews/cordlife_05OCT07.pdf Minister of Health Opens Umbilical Cord Blood Bank Cordlife Indonesia] {{Webarchive|url=https://web.archive.org/web/20140504085339/http://www.cordlife.com/news/pdf_cordlifeNews/cordlife_05OCT07.pdf |date=2014-05-04 }}", 5 October 2007 </ref> cord blood units. Cordlife Indonesia also has branch offices in Medan, Surabaya and Bandung. PT.Cordlife Persada has become the first in Indonesia to join the ranks of world-class cord blood banks as an AABB accredited facility. With Cordlife Indonesia's new AABB accreditation status, Cordlife clients in Indonesia can now opt to have their transplant or infusion done in countries such as United States and Singapore, where only cord blood units (if imported) handled by AABB or its equivalent accredited facilities, will be permitted or preferred for use.
=== India === Cordlife Group owns a majority interest (99.9%<ref> {{Cite web|url=http://cordlife.listedcompany.com/misc/ar2016/index.html|title=Cordlife Group Limited Annual Report 2017|archive-url=https://web.archive.org/web/20180521010002/http://cordlife.listedcompany.com/misc/ar2016/index.html|archive-date=2018-05-21|url-status=live|access-date=15 May 2018}} </ref>) in Cordlife Sciences (India) Pvt. Ltd., (“Cordlife India”) through its wholly owned subsidiary CS Cell Technologies Pte. Ltd. Established in Kolkata, Cordlife India's cord blood facility has a storage capacity of up to 150,000<ref> SBWire, "[http://www.sbwire.com/press-releases/cordlife-india-offers-most-advanced-cord-blood-facility-with-cordlife-quality-guarantee-163755.htm CordLife India Offers Most Advanced Cord Blood Facility with CordLife Quality Guarantee] {{Webarchive|url=https://web.archive.org/web/20140504103706/http://www.sbwire.com/press-releases/cordlife-india-offers-most-advanced-cord-blood-facility-with-cordlife-quality-guarantee-163755.htm |date=2014-05-04 }}", 10 July 2012 </ref> cord blood units. In July 2013,<ref name=":7" /> Cordlife India attained accreditation from AABB, an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The facility is also certified by ISO 9001:2008.<ref name=":6"> Cordlife Press Release, "[http://cordlife.listedcompany.com/newsroom/20130704_185540_P8A_8F58FD09456583A548257B9E00362C06.1.pdf Cordlife India Obtains AABB Accreditation] {{Webarchive|url=https://web.archive.org/web/20140503100038/http://cordlife.listedcompany.com/newsroom/20130704_185540_P8A_8F58FD09456583A548257B9E00362C06.1.pdf|date=2014-05-03}}" </ref> In 2011,<ref> Express Healthcare, "[http://healthcare.financialexpress.com/201106/market13.shtml India’s First Successful Mixed Stemcell Transplant From CordLife] {{Webarchive|url=https://web.archive.org/web/20140504085259/http://healthcare.financialexpress.com/201106/market13.shtml |date=2014-05-04 }}", June 2011 </ref> Cordlife India successfully released a stem cell unit for the first ever mixed stem cell transplant in India. Cordlife India introduced an advanced non-invasive newborn metabolic screening test called Metascreen in India in October 2013.<ref name=":4" />
=== The Philippines === Cordlife Group owns a 99.99%<ref name=":11"> Cordlife Press Release, "[http://cordlife.listedcompany.com/newsroom/20130628_171650_P8A_1048917DF1D4F86E48257B97002B6BCA.1.pdf Cordlife Completes Acquisition of Cord Blood and Cord Tissue Banking Businesses and Assets in India, The Philippines, Hong Kong and Indonesia] {{Webarchive|url=https://web.archive.org/web/20140503100041/http://cordlife.listedcompany.com/newsroom/20130628_171650_P8A_1048917DF1D4F86E48257B97002B6BCA.1.pdf|date=2014-05-03}}", 28 June 2013 </ref> interest in Cordlife Medical Phils., Inc. (“Cordlife Philippines”), through its wholly owned subsidiary CS Cell Technologies Pte. Ltd. Registered with the Department of Health, Cordlife Philippines' ISO-certified and AABB<ref name=":7" />-accredited facility cord blood processing and cryopreservation facility was officially launched in February 2010 with a storage capacity for 20,000<ref> PhilStar, "[http://www.philstar.com/health-and-family/557971/saving-cells-count Saving the cells that count] {{Webarchive|url=https://web.archive.org/web/20140504090355/http://www.philstar.com/health-and-family/557971/saving-cells-count |date=2014-05-04 }}", 16 March 2010 </ref> cord blood units. In August 2013,<ref name=":12"> Smart Parenting Philippines, "[http://www.smartparenting.com.ph/pregnancy/labor-and-childbirth/cordlife-philippines-launches-affordable-umbilical-cord-banking-services Cordlife Philippines Launches Affordable Umbilical Cord Banking Services] {{Webarchive|url=https://web.archive.org/web/20140504073028/http://www.smartparenting.com.ph/pregnancy/labor-and-childbirth/cordlife-philippines-launches-affordable-umbilical-cord-banking-services |date=2014-05-04 }}", 3 September 2013 </ref> Cordlife Philippines officially launched its newest service, umbilical cord lining banking.
=== Malaysia === Established in 2001 and headquartered in Kuala Lumpur, Malaysia's largest cord blood banking operator StemLife, is the first stem cell banking and therapeutics company in Malaysia. Stemlife became a majority-owned subsidiary of Cordlife Group Limited in December 2015. StemLife operates its own 24-hour processing, testing, and cryopreservation facility in central Kuala Lumpur, Malaysia. They have successfully released 16 cord blood units for transplantation and infusion.
==References== {{Reflist}}
Category:2001 establishments in Singapore Category:Health care companies of Singapore Category:Companies listed on the Singapore Exchange Category:Singaporean brands